<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03301896</url>
  </required_header>
  <id_info>
    <org_study_id>CLHC165X2101</org_study_id>
    <nct_id>NCT03301896</nct_id>
  </id_info>
  <brief_title>Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies</brief_title>
  <official_title>A Phase I/Ib, Open-label, Multi-center Dose-escalation and Dose-expansion Study of the Safety and Tolerability of Intra-tumorally Administered LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to explore the clinical utility of two investigational agents in&#xD;
      patients with advanced cancer.&#xD;
&#xD;
      This is a multi-center, open-label Phase I/Ib study. The study consists of four dose&#xD;
      escalation parts and two dose expansion parts testing LHC165 as a single agent or LHC165 in&#xD;
      combination with PDR001. The dose escalation parts will estimate the Maximum Tolerated Dose&#xD;
      (MTD) and/or Recommended Dose for Expansion (RDE) and test two different dosing schedules for&#xD;
      LHC165.&#xD;
&#xD;
      The dose expansion parts of the study will use the MTD/RDE for each the LHC165 single agent&#xD;
      and in combination with PDR001, determined in the respective dose escalation parts to assess&#xD;
      the activity, safety and tolerability of LHC165 as a single agent or LHC165 in combination&#xD;
      with PDR001 in patients with specific types of solid tumors.&#xD;
&#xD;
      Approximately 206 adult patients with advanced solid tumors will be enrolled.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase I/Ib, multi-center, open-label study to characterize the safety,&#xD;
      tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor&#xD;
      activity of LHC165 single agent and in combination with the Programmed Cell Death Protein-1&#xD;
      (PD-1) checkpoint inhibitor PDR001. Two different dosing schedules will be explored for&#xD;
      LHC165 single agent and in combination with PDR001 resulting in four dose escalation groups&#xD;
      in accessible tumors. The first dose escalation group will receive LHC165 via intratumoral&#xD;
      injection on Days 1 and 15 of Cycles 1, 2, 5, and 6. If biological activity is seen in the&#xD;
      LHC165 single agent group on the biweekly dosing schedule, another dose escalation group&#xD;
      using a monthly dosing schedule will be opened where patients will receive LHC165 via&#xD;
      intratumoral injection on Day 1 of Cycles 1, 2, 5, and 6. In addition, once two safe doses&#xD;
      are observed in the LHC165 single agent group on the biweekly dosing schedule, an LHC165&#xD;
      combination with PDR001 dose escalation group will be opened using the biweekly dosing&#xD;
      schedule. If biological activity is seen in the LHC165 combination with PDR001 group on the&#xD;
      biweekly dosing schedule, another dose escalation group for the combination using a monthly&#xD;
      dosing schedule will be opened.&#xD;
&#xD;
      Once the recommended dose for the LHC165 single agent and in combination with PDR001 is&#xD;
      identified, the respective expansion parts of the study will open.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 31, 2018</start_date>
  <completion_date type="Anticipated">March 21, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 21, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Escalation: Incidence of Dose-limiting Toxicities (DLTs) in Cycle 1</measure>
    <time_frame>day 28</time_frame>
    <description>Dose Limiting Toxicity Evaluation Period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Escalation and Expansion: Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs), including changes in laboratory parameters, vital signs, electrocardiograms (ECGs)</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) per RECIST 1.1 and iRECIST</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response (BOR) per RECIST 1.1 and iRECIST</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS) per RECIST 1.1 and iRECIST</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) per RECIST 1.1 and iRECIST</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR) per RECIST 1.1 and iRECIST</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration profiles of LHC165 as a single agent: Cmax</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration profiles of LHC165 in combination with PDR001 and derived PK parameters: Cmax</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration profiles of PDR001 in combination with LHC165 and derived PK parameters: Cmax</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration profiles of LHC165 as a single agent: AUC</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration profiles of LHC165 in combination with PDR001 and derived PK parameters: AUC</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration profiles of PDR001 in combination with LHC165 and derived PK parameters: AUC</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration profiles of LHC165 as a single agent: Tmax</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration profiles of LHC165 in combination with PDR001 and derived PK parameters: Tmax</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration profiles of PDR001 in combination with LHC165 and derived PK parameters: Tmax</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence and titer of anti-PDR001 antibodies</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in tumor infiltrating lymphocytes in injected and distal tumor specimens</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>LHC165 single agent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LHC165 intratumoral injection given alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LHC165 in combination with PDR001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LHC165 intratumoral injection given with PDR001 infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LHC165</intervention_name>
    <description>LHC165 intratumoral injection</description>
    <arm_group_label>LHC165 in combination with PDR001</arm_group_label>
    <arm_group_label>LHC165 single agent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PDR001</intervention_name>
    <description>PDR001 infusion</description>
    <arm_group_label>LHC165 in combination with PDR001</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent must be obtained prior to any procedures unless considered&#xD;
             standard of care.&#xD;
&#xD;
          -  Adult men and women (≥ 18 years of age) with histologically confirmed diagnosis of&#xD;
             metastatic and/or advanced solid tumors not amenable to curative treatment by surgery.&#xD;
&#xD;
          -  Patients must be willing and able to comply with the protocol for the duration of the&#xD;
             study including undergoing treatment and scheduled visits and examinations including&#xD;
             follow up.&#xD;
&#xD;
          -  Dose escalation: Patients with accessible tumors and with measurable disease as&#xD;
             determined by RECIST 1.1 and have progressed despite standard treatment or are&#xD;
             intolerant of standard treatment, or for whom no standard treatment exists.&#xD;
&#xD;
          -  Dose expansion: Patients with advanced/metastatic solid tumors: HNSCC, melanoma,&#xD;
             accessible tumors and visceral tumors (LHC165 combination with PDR001 only). Patients&#xD;
             must have measurable disease as determined by RECIST 1.1 and have progressed despite&#xD;
             standard treatment or are intolerant to standard treatment, or for whom no standard&#xD;
             treatment exists• Patients must have at least two sites of disease amenable to biopsy.&#xD;
&#xD;
          -  Patient has an Eastern Cooperative Oncology Group (ECOG) performance status 0-2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of symptomatic or uncontrolled central nervous system (CNS) metastases&#xD;
             requiring local CNS-directed treatment.&#xD;
&#xD;
          -  Patients diagnosed with hematological malignancies.&#xD;
&#xD;
          -  Patients with prior stem cell transplants.&#xD;
&#xD;
          -  Patients previously treated with TLR-7/8 agonist treatment.&#xD;
&#xD;
          -  History of primary immunodeficiency&#xD;
&#xD;
          -  Patients who discontinued prior anti-PD-1/PD-L1 therapy due to an&#xD;
             anti-PD-1/PD-L1-related toxicity.&#xD;
&#xD;
          -  Malignant disease, other than that being treated in this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nehal Parikh, MD</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wilrijk</city>
        <zip>2610</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chuo ku</city>
        <state>Tokyo</state>
        <zip>104 0045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
    <country>France</country>
  </removed_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 29, 2017</study_first_submitted>
  <study_first_submitted_qc>September 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2017</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase I</keyword>
  <keyword>LHC165</keyword>
  <keyword>PDR001</keyword>
  <keyword>intratumoral injection</keyword>
  <keyword>abscopal</keyword>
  <keyword>checkpoint inhibitor</keyword>
  <keyword>programmed cell death</keyword>
  <keyword>PD-1</keyword>
  <keyword>TLR-7</keyword>
  <keyword>toll-like receptor</keyword>
  <keyword>melanoma</keyword>
  <keyword>head and neck</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spartalizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

